Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Bendamustine + Rituximab With or Without Acalabrutinib in Previously Untreated Mantle Cell Lymphoma
jRCT2080224061Phase 3Completed
- Sponsor
- Acerta Pharma
- Start
- Sep 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in mantle cell lymphoma (MCL) comparing Acalabrutinib + bendamustine + rituximab with Placebo + bendamustine + rituximab (2 arms). Started Sep 2018; status: completed.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on jRCT2080224061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224061.